登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603388 证券简称：*ST元成 公告编号：2025-137 元成环境股份有限公司 股票严重交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 元成环境股份有限公司（以下简称"公司"）股票连续30个交易日内日收盘价格跌幅偏离值累计超过 70%，属于股票交易严重异常波动的情形。 ● 交易类强制退市风险。公司股票2025年11月6日收盘总市值为2.08亿元，已连续18个交易日总市值低 于5亿元，即使后续2个交易日（不包含公司股票全天停牌日）连续涨停，也将因连续20个交易日收盘总 市值低于5亿元而触及交易类强制退市。根据《股票上市规则》第9.2.1条第一款第（五）项的规定，上 市公司出现连续20个交易日在上海证券交易所（以下简称"上交所"）的每日股票收盘总市值均低于5亿 元情形的，上交所将决定终止公司股票上市，属于交易类强制退市。 公司股票2025年11月6日收盘价为0.64元，已连续9个交易日低于1元。根据《股票上市规则》第9.2.1条 ...

Group 1 - The company's stock experienced an unusual fluctuation, with a cumulative price increase deviation of 16.19% over three consecutive trading days from November 3 to 5, 2025 [1] - For the first three quarters of 2025, the company reported revenue of 134.71 million yuan, a year-on-year decrease of 52.64% [1] - The total profit for the same period was -151.07 million yuan, reflecting a year-on-year decline of 41.83% [1] Group 2 - The company's net profit after deducting non-recurring items was -132.35 million yuan, down 34.12% year-on-year [1] - There is a risk of being subject to delisting warning if the audited indicators for the year 2025 do not meet the standards [1] - The auction of shares by the controlling shareholder has been completed, and further procedures are required, indicating a potential change in control [1]

每经记者｜闫峰峰 每经编辑｜陈柯名 吴永久 *ST亚振以一场"10倍股"的行情引起市场关注。在短短半年多时间里，这只连续四年亏损、被实施退市风险警示的个股，完成了近10倍的涨幅。在上涨行 情启动前一年，公司股东户数从2.52万户锐减至1.41万户，筹码快速集中；而股价上涨初期，公司筹码集中现象更是加速，股东户数在一个季度时间便出 现了腰斩。 这场资本盛宴始于2025年4月的新实控人入驻——吴涛及一致行动人以5.68元/股的价格收购公司50.47%股权。8月，*ST亚振收购了广西锆业51%股权，这 进一步催化了公司股价的上涨。然而，公司前三季度仍亏损3141万元，退市风险仍未消除。 不过自4月低点之后，公司的股价便开启了长牛走势，最高涨至近期的高点48.55元。期间最大涨幅达991%。 值得注意的是，公司的股东户数，在本轮股价大涨的初期，出现了更为剧烈的减少：公司的股价在今年二季度上涨了240.5%，突破了此前6年的高点，与 此同时，公司的股东户数从今年一季度末的14418户大幅减少至今年二季度末的7286户，下降幅度达49%。而这意味着，在公司股价上涨初期，公司的股 份加速向少部分人集中。 而回顾*ST亚振的 ...

Core Viewpoint - *ST亚振 has experienced a dramatic stock price increase, rising nearly 10 times within a short period, despite ongoing financial losses and delisting risks [1][5][10] Group 1: Stock Performance - The stock price surged from a low of 4.45 yuan in April to a high of 48.55 yuan, marking a maximum increase of 991% [2][3] - The stock saw a significant drop in shareholder accounts, decreasing from 25,240 to 14,418 over one year, a decline of 42% [2][3] - In the initial phase of the stock price increase, shareholder accounts halved from 14,418 to 7,286, a drop of 49% [3][4] Group 2: Shareholder Dynamics - The reduction in shareholder accounts indicates a concentration of ownership prior to the stock price surge [2][3] - By the end of the third quarter, the number of shareholders increased to 10,220, suggesting a potential distribution of shares [4] Group 3: Company Developments - The stock price rally began after a change in control, with new major shareholders acquiring 50.47% of the company at 5.68 yuan per share [1][5][8] - The company announced a cash acquisition of 51% of Guangxi Zirconium Industry, which further fueled the stock price increase [1][8] - Despite the stock price increase, the company reported a net loss of 31.41 million yuan for the first three quarters of the year [9] Group 4: Regulatory and Risk Factors - The company has faced multiple negative announcements regarding potential delisting risks, including a warning about continuous losses [5][10] - The stock was placed under delisting risk warnings due to failing to meet financial performance criteria [10]

Core Viewpoint - *ST Suwu is facing significant challenges, including a sharp decline in revenue and net profit, alongside ongoing arbitration regarding the exclusive agency rights for the AestheFill product, which is critical to its business operations [2][5][6]. Financial Performance - In Q3 2025, *ST Suwu reported a revenue decline of 63.93% year-on-year, amounting to 148 million yuan, with a net profit attributable to shareholders of approximately -43 million yuan, a drastic decrease of 308.72% compared to the previous year [2][4]. - For the first three quarters of the year, the company's revenue fell by 38.85% to 784 million yuan, and the net profit decreased by 294.03% to -87.47 million yuan, primarily due to significant impairment provisions for trade receivables [5][6]. Business Segments - The pharmaceutical business generated a total revenue of 468 million yuan, down 55.79% year-on-year, while the aesthetic biomedical segment achieved a revenue of 304 million yuan, reflecting a growth of 52.78% [5][6]. - The AestheFill product, crucial for the aesthetic segment, faced sales disruptions due to an ongoing arbitration case, which has created uncertainty for the company's future performance in this area [6][7]. Regulatory and Legal Issues - *ST Suwu is under scrutiny from the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure, leading to a formal investigation and potential penalties [7][9]. - The company has been implicated in inflating revenue figures by approximately 1.771 billion yuan from 2020 to 2023, raising concerns about its financial integrity and leading to multiple delisting risks [8][9]. Management Changes - Recent changes in the company's management include the resignation of the securities affairs representative, with a new appointment made to assist the board in fulfilling its responsibilities [9].

Core Viewpoint - *ST Suwu is facing significant challenges, including a sharp decline in revenue and net profit, alongside multiple delisting risks, particularly related to the arbitration case concerning the exclusive agency rights for the AestheFill product. Financial Performance - In Q3 2025, *ST Suwu reported a revenue decline of 63.93% year-on-year to 148 million yuan, with a net profit attributable to shareholders of approximately -43.05 million yuan, a drastic decrease of 308.72% compared to the same period last year [1][3] - For the first three quarters, the company's revenue fell by 38.85% to 784 million yuan, and the net profit decreased by 294.03% to -87.47 million yuan, primarily due to significant impairment provisions for trade receivables [4][5] - The pharmaceutical business generated a total revenue of 468 million yuan, down 55.79% year-on-year, while the medical aesthetics sector achieved a revenue of 304 million yuan, up 52.78% [4] Business Operations - The decline in revenue is attributed to a significant drop in income from pharmaceutical and medical aesthetics businesses, with the company admitting it is currently unable to continue selling AestheFill products due to ongoing arbitration [1][5] - AestheFill, a key product for *ST Suwu, was launched in 2024 and contributed significantly to the company's revenue, accounting for 35.55% of total revenue in Q1 2024 [5][6] Legal and Regulatory Issues - *ST Suwu is under scrutiny for alleged information disclosure violations, having received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation [7] - The company has been found to have inflated revenue by approximately 1.771 billion yuan from 2020 to 2023 through non-commercial trade activities, leading to multiple delisting risks [8][9] - The company has faced a series of legal challenges, including a criminal case against its subsidiary for tax fraud, which further complicates its financial situation [9]

Core Viewpoint - The company, Lifan Technology, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure related to its periodic report, with the investigation ongoing and no conclusive opinions or decisions received yet [1] Group 1 - The investigation was initiated on April 28, 2025, due to allegations of information disclosure violations [1] - The company's operational status remains normal despite the ongoing investigation [1] - If the CSRC determines that significant violations have occurred, the company may face mandatory delisting due to serious legal infractions [1]

Core Points - The company's stock price has increased by 76.78% since October 15, 2025, with a 34.21% rise over six consecutive trading days from October 27 to November 3, 2025, despite unchanged fundamentals [1] - There are risks of stock suspension and delisting due to unresolved non-operating fund occupation issues by related parties, with a termination of the repayment plan for these funds [1] - The controlling shareholder and related parties have a high percentage of shares frozen, marked, and pledged [1] - The company reported a net loss of 133.78 million yuan for 2024, a decrease of 354.59%, and a net profit of 16.44 million yuan for the first three quarters of 2025, down 60.93% [1]

Core Viewpoint - Jiangsu Wuzhong (ST Suwu) is facing imminent delisting risks due to significant financial misconduct and operational decline, with a potential forced delisting warning issued by the China Securities Regulatory Commission (CSRC) [2][5] Financial Performance - For the first three quarters, Jiangsu Wuzhong reported a net loss of 87.468 million yuan, with revenue decreasing by nearly 40% year-on-year, leading to a cumulative loss of 500 million yuan in undistributed profits [2][6] - The company's revenue for the first three quarters was 784 million yuan, a year-on-year decrease of 38.85%, with a net profit loss of 94.7225 million yuan after excluding non-recurring items [6][7] Legal and Regulatory Issues - The CSRC has identified Jiangsu Wuzhong's major violations, including failure to disclose the actual controller, inflating revenue and profits, and not reporting non-operating fund occupation by related parties [3][5] - The company has been under investigation since February, and its stock price has dropped 88% since then, with the latest closing price at 0.99 yuan [5][6] Operational Challenges - Jiangsu Wuzhong's core pharmaceutical business has seen a 55.79% decline in revenue, while its medical beauty segment, once seen as a growth driver, is now at risk due to the termination of exclusive distribution rights for its key product, AestheFill [7][8] - The company is experiencing severe cash flow issues, with operational capabilities severely hampered by the occupation of funds by related parties, which increased from 127 million yuan at the end of 2020 to 1.693 billion yuan by the end of 2023 [4][6] Shareholder Impact - As of September 30, Jiangsu Wuzhong had 67,400 shareholders, facing imminent delisting risks if the CSRC confirms the violations or if the stock price remains below 1 yuan for 20 consecutive trading days [8]

Core Viewpoint - Jiangsu Wuzhong (*ST Suwu*) is facing imminent delisting risks due to significant financial losses, operational stagnation, and regulatory violations, with a net profit loss of 87.468 million yuan and a nearly 40% year-on-year revenue decline in the third quarter [3][4]. Group 1: Delisting Risks - The primary risk for Jiangsu Wuzhong is the potential for mandatory delisting due to major violations, as identified by the China Securities Regulatory Commission (CSRC) [5]. - The company has been found guilty of three major violations, including failing to disclose the actual controller, inflating revenue and profits, and not reporting non-operational fund usage by related parties [5][6]. - The stock price has plummeted 88% since the CSRC investigation began, with the latest closing price at 0.99 yuan, hovering near the delisting threshold of 1 yuan [7]. Group 2: Financial Performance - Jiangsu Wuzhong reported a 38.85% decrease in revenue for the first three quarters, totaling 784 million yuan, with a net profit loss of 87.468 million yuan [9]. - The third quarter alone saw a staggering 63.93% year-on-year revenue drop, with a net profit loss of 43.0502 million yuan, marking a significant operational decline [9][10]. - The company's cumulative undistributed losses reached 505 million yuan by the end of the third quarter, the highest since its listing [9]. Group 3: Business Operations - The core pharmaceutical business has seen a 55.79% decline in revenue, while the medical beauty segment, previously seen as a growth driver, is now at risk due to the termination of exclusive distribution rights for a key product [10][11]. - The medical beauty segment's revenue was 303 million yuan, a 52.78% increase, but the loss of exclusive rights for the AestheFill product could severely impact future earnings [10][11]. - The company is facing severe cash flow issues, with operational funds critically low due to significant related party fund usage, which increased from 127 million yuan in 2020 to 1.693 billion yuan in 2023, consuming nearly all net assets [6][9].